Bruton’s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)

Keyphrases

• Adverse Events 20%
• Area Cover 20%
• Atrial Fibrillation 20%
• Bruton's Tyrosine Kinase Inhibitors (BTKi) 100%
• BTK Inhibitors 60%
• Chemoimmunotherapy 20%
• Chronic Lymphocytic Leukemia 100%
• Combination Strategy 20%
• Combination Therapy 20%
• Continuous Therapy 20%
• Durable Remission 20%
• Efficacy Safety 20%
• Expert Opinion 20%
• First-line Regimen 20%
• Generation Agent 100%
• Great Depth 20%
• Hemorrhage 20%
• High Efficacy 20%
• High Risk 40%
• Ibrutinib 100%
• Inpatient Treatment 20%
• Kinase Inhibition 20%
• Leukemia Patients 40%
• Low Risk 20%
• Maintenance Risk 20%
• Maintenance Therapy 20%
• Maintenance Treatment 20%
• Myelotoxicity 20%
• Novel Combinations 20%
• Older Patients 20%
• Overall Safety 20%
• Previously Treated 20%
• Relapsed Chronic Lymphocytic Leukaemia 20%
• Remission 20%
• Therapeutic Development 20%
• Treatment Cessation 20%
• Treatment Discontinuation 20%
• Treatment Interruption 20%
• Treatment Resistance 20%
• Unfit Patients 40%
• Venetoclax 20%
• Well Tolerated 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 20%
• Atrial Fibrillation 20%
• Bone Marrow Toxicity 20%
• Bruton Tyrosine Kinase Inhibitor 100%
• Chronic Lymphatic Leukemia 100%
• Combination Therapy 20%
• Ibrutinib 100%
• Phosphotransferase 20%
• Remission 40%
• Side Effect 20%
• Venetoclax 20%